SCHEMBL16189136

SCHEMBL16189136

Cc1cc(C)nc(-c2cc(-c3nc(-c4ccccc4)nc(-c4ccccc4)n3)cc(-c3c4ccccc4cc4ccccc34)c2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
NPC1 O15118 1/20 0.46
GBA1 P04062 1/20 0.46
RAB9A P51151 1/20 0.46
ABCG2 Q9UNQ0 8/20 0.45
MAPT P10636 4/20 0.45
MAPK1 P28482 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
CYP2C19 P33261 1/20 0.45
ATM Q13315 1/20 0.45
TSHR P16473 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HSD17B10 Q99714 1/20 0.41
FFAR1 O14842 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17532812 0.96 LMNA (0.46) LMNAL3MBTL1KMT2AMEN1NPC1
SCHEMBL16189134 0.96 LMNA (0.46) LMNAL3MBTL1KMT2AMEN1NPC1
SCHEMBL17532810 0.94 LMNA (0.45) LMNAL3MBTL1KMT2AMEN1NPC1
SCHEMBL17532839 0.91 LMNA (0.44) LMNAL3MBTL1KMT2AMEN1NPC1
SCHEMBL9958607 0.90 ALOX5 (0.46) LMNAL3MBTL1KMT2AMEN1NPC1
SCHEMBL16189270 0.90 LMNA (0.43) LMNAL3MBTL1KMT2AMEN1NPC1
SCHEMBL16189533 0.90 LMNA (0.43) LMNAL3MBTL1KMT2AMEN1NPC1
SCHEMBL16189339 0.89 MEN1 (0.44) LMNAL3MBTL1KMT2AMEN1NPC1
SCHEMBL16189148 0.89 MEN1 (0.44) LMNAL3MBTL1KMT2AMEN1NPC1
SCHEMBL17932321 0.87 ALOX5 (0.43) LMNAL3MBTL1KMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed
WO-2014171541-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE ELEMENT AND APPLICATION THEREFOR 東ソー株式会社 (JP) 2014-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION AOC2, AZI2, KCNH2 LMNA 2238/4885L3MBTL1 997/4885KMT2A 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.